Compare DexCom, Inc. (DXCM) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Jumia Technologies AG - ADR — how do they compare? DexCom, Inc. trades at $77.3 (market cap $28.06B), while Jumia Technologies AG - ADR trades at $6.53 (market cap $848.39M). The key difference: DexCom, Inc. is far larger — about 33.1× Jumia Technologies AG - ADR's market cap, and DexCom, Inc. is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals.
| DXCM | JMIA | |
|---|---|---|
Market Cap | $28.06B | $848.39M |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $14.60 |
52-Week Low | $54.84 | $4.45 |
Enterprise Value | $27.03B | $795.49M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
JMIA trades at $6.52, down 4.82% today, amid a bearish technical signal. The company reported Q1 2026 revenue growth of 39% year-over-year but missed EPS estimates, with a net income margin of -30.79%. Cash flow improved in 2025, yet profitability remains elusive with a target set for 2027. Analyst consensus is strongly bullish with 71% buy ratings, highlighting progress in African e-commerce expansion and partnerships like Starlink.
Outlook: JMIA shows operational improvements but faces significant execution risks in achieving profitability. Investment opportunity lies in market expansion and cost management, while risks include persistent losses, competitive pressures, and macroeconomic volatility in Africa. The stock's valuation at P/S of 4.17 reflects growth expectations amid high uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
